Transparency Declaration From Several Major Shareholders
Liege (Belgium) - October 20, 2008, 8:30 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that it has received transparency declarations from several major shareholders pursuant to the new transparency legislation (Belgian Act of May 2, 2007) concerning major holdings in issuers whose shares are admitted to trading on a regulated Belgian market.
OncoMethylome has 11.808.822 shares outstanding. The following shareholders have informed OncoMethylome of their holdings as of September 1, 2008:
|
Shareholder |
Number of shares |
% of outstanding shares |
|
Technowal SA |
375.560 |
3.18 |
|
Life Sciences Partners II BV |
1.411.195 |
11.96 |
|
Edmond de Rothschild Investment Partners |
947.580 |
8.02 |
|
ING Belgium NV/SA |
2.147.610 |
18.19 |
|
Herman Spolders |
432.500 |
3.66 |
|
Polytechnos Venture Partners II GmbH |
813.050 |
6.89 |
The above parties made their declarations separately and are acting independently. Edmond de Rothschild Investment Partners and Polytechnos Venture Partners II GmbH are advisors to funds that hold OncoMethylome shares and do not hold shares directly in their own name.
"The above shareholders have been holders of OncoMethylome shares for several years and we welcome the support they have brought to our company. Their diverse geographical representation (France, the Netherlands, Germany, and Belgium) is consistent with OncoMethylome's international leadership in the field of molecular cancer diagnostics" stated Philip Devine, CFO of OncoMethylome.
To download this press release as a PDF, click here: Press Release
About OncoMethylome Sciences
OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.
OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, and Millipore Corporation's BioScience Division. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).
Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).
For more information please contact:
Philip Devine
Tel. +32-479-505-885
